MERREM IV (meropenem) by Pfizer is [ see microbiology () ]. First approved in 1996.
Drug data last refreshed 4d ago
[ see Microbiology () ].
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Study to Evaluate the Efficacy and Safety of Meropenem and Pralurbactam in HABP/VABP
Assess the Plasma, Epithelial Lining, and Alveolar Macrophage Concentrations of Intravenous Meropenem-Pralubactam (Meropenem/FL058) in China Healthy Adult Participants
Cefepime-taniborbactam vs Meropenem in Adults With VABP or Ventilated HABP
Evaluation of the Concentration of ANT3310 and Meropenem in the Lung in Healthy Adult Participants
Study to Assess the Efficacy and Safety of Meropenem and Pralurbactam in Carbapenem-Resistant Enterobacteriaceae Infections
Worked on MERREM IV at Pfizer? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Upgrade to Pro to access CMS Part B ASP pricing data and other premium pharma intelligence.
Upgrade to Pro — $25/mo